drugset
drugset / Trial / NCT06387628

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

NCT06387628 ↗

Phase 2 Recruiting 74 enrolled Fudan University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.

Timeline

Start
2024-07-10
Primary completion
2026-04-01
Completion
2027-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CAFELKIBART Monoclonal antibody 10 mg/kg —
Subject Eribulin Small molecule 1.4 mg/m2 —
Subject Paclitaxel Small molecule 125 mg/m2 —
Subject Toripalimab Monoclonal antibody 240 mg —

Indications

triple-negative breast carcinoma